Breast Cancer is one the most common types of cancer in the UK. It is predicted that 1 in 7 women will be affected by the illness in their lifetime. Research at the University of Salford has uncovered important findings on how to effectively target mitochondriawhich normally provide all the necessary energy for driving the proliferation and dissemination of cancer stem cells.
The potential benefits of receiving cancer treatment must be carefully balanced with the potential risks of receiving cancer treatment. The following is a general overview of high-dose chemotherapy and autologous stem cell transplant for the treatment of stage II-III breast cancer. Circumstances unique to your situation and prognostic factors of your cancer may ultimately influence how these general treatment principles are applied.
Scientists have discovered a new stem cell-based cancer treatment that can target and kill breast cancer cells that have spread in mice. The researchers at the University of California Irvine UCI also hope that the new treatment may prevent some of the toxic side-effects of chemotherapy by providing a more localised therapy. Associate professor of pharmaceutical sciences at UCI, Weian Zhao says they have effectively and safely employed the stem cell technology in mice to treat metastatic breast cancer that had spread to the lungs.
A new long-term study of women with stage-4 breast cancer at the Stanford University School of Medicine is likely to revive a decade-old debate about high-dose chemotherapy as a treatment option. Specifically, researchers found that a greater proportion of patients who received the aggressive treatment 12 to 14 years ago, followed by a rescue with their own, specially purified blood stem cells that had been purged of cancer, survived compared with those who were rescued with unmanipulated blood grafts. The study, although small, is the first to analyze the long-term outcomes of women who received their own autologous stem cells that had undergone this purification process. While high-dose chemotherapy followed by autologous blood stem cell transplantation was largely discarded at the end of the s — interim analyses of several then-ongoing phase-3 clinical trials suggested it produced no better outcomes than other forms of treatment — women in this report received blood stem cells that had been prepared very differently.
The potential benefits of receiving cancer treatment must be carefully balanced with the potential risks of receiving cancer treatment. The following is a general overview of high-dose chemotherapy and autologous stem cell transplant for the treatment of stage IV breast cancer. Circumstances unique to your situation and prognostic factors of your cancer may ultimately influence how these general treatment principles are applied.
Continuing with Breast Cancer Awareness Month, we look at stem cells in breast cancer and the role these often mysterious entities play in the disease. A single breast cancer is composed of many different cell types. In addition to cancer cells, these include non-cancerous support cells, blood vessels and various immune cells.
How is stem cell research changing the lives of breast cancer patients? And the strangest thing — I If you visit the Chicago Air Museum now called the Museum of Science and Industry you can see the actual plane the Wright brothers flew, on the
Various types of cancer can become particularly aggressive and difficult to treat once they spread from their initial point of origin to other parts of the body. This unfortunate phenomenon, known as metastasis, can make treatment very challenging, decreasing the chance of survival for the patient. In order to better understand this process, a CIRM supported study at USC looked at breast cancer cells circulating in the blood that eventually invade the brain.
January 25, Up to 75 percent of women diagnosed with breast cancer will have a cancer driven by oestrogen signalling and almost all of these women will receive anti-hormone therapylike Tamoxifen or Aromatase inhibitors, to treat their cancer. Unfortunately, up to 40 percent of patients receiving these hormone therapies will develop a resistance to them, leading to relapse with aggressive cancer.